These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 22040919)

  • 1. Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor.
    Iwatsuki Y; Sato T; Moritani Y; Shigenaga T; Suzuki M; Kawasaki T; Funatsu T; Kaku S
    Eur J Pharmacol; 2011 Dec; 673(1-3):49-55. PubMed ID: 22040919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic and anticoagulant effects of direct factor Xa inhibitor darexaban in rat and rabbit models of venous thrombosis.
    Kaku S; Uemura T; Saitoh M; Suzuki K; Iwatsuki Y; Funatsu T; Kawasaki T
    Eur J Pharmacol; 2013 Jan; 699(1-3):40-7. PubMed ID: 23200896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma factor Xa inhibition can predict antithrombotic effects of oral direct factor Xa inhibitors in rabbit atherothrombosis models.
    Funatsu T; Yamashita A; Kaku S; Iwatsuki Y; Asada Y
    Thromb Haemost; 2012 Nov; 108(5):896-902. PubMed ID: 23052641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Darexaban: anticoagulant effects in mice and human plasma in vitro, antithrombotic effects in thrombosis and bleeding models in mice and effects of anti-inhibitor coagulant complex and recombinant factor VIIa.
    Kaku S; Suzuki M; Saitoh M; Funatsu T; Uemura T; Suzuki K; Iwatsuki Y; Kawasaki T
    Thromb Res; 2013 May; 131(5):450-6. PubMed ID: 23591155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor.
    Hirayama F; Koshio H; Ishihara T; Hachiya S; Sugasawa K; Koga Y; Seki N; Shiraki R; Shigenaga T; Iwatsuki Y; Moritani Y; Mori K; Kadokura T; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
    J Med Chem; 2011 Dec; 54(23):8051-65. PubMed ID: 21995444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
    Kawamura M; Konishi N; Hiroe K; Shofuda K; Imaeda Y; Fujimoto T; Kubo K
    J Cardiovasc Pharmacol; 2010 Aug; 56(2):156-61. PubMed ID: 20410831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of UDP-glucuronosyltransferases responsible for the glucuronidation of darexaban, an oral factor Xa inhibitor, in human liver and intestine.
    Shiraga T; Yajima K; Suzuki K; Suzuki K; Hashimoto T; Iwatsubo T; Miyashita A; Usui T
    Drug Metab Dispos; 2012 Feb; 40(2):276-82. PubMed ID: 22031623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor.
    Abboud MA; Needle SJ; Burns-Kurtis CL; Valocik RE; Koster PF; Amour AJ; Chan C; Brown D; Chaudry L; Zhou P; Patikis A; Patel C; Pateman AJ; Young RJ; Watson NS; Toomey JR
    J Cardiovasc Pharmacol; 2008 Jul; 52(1):66-71. PubMed ID: 18645410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological characterization of the active synthetic factor Xa inhibitors M55551 and M55165.
    Hosaka Y; Matsumoto M; Shinozaki M; Ohno T; Yatagai Y; Kamiya M; Kurokawa M; Nishida H; Matsusue T; Mizuguchi K; Ishii H
    Eur J Pharmacol; 2006 Jan; 529(1-3):164-71. PubMed ID: 16316651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
    Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
    Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans.
    Hashimoto T; Suzuki K; Kihara Y; Iwatsubo T; Miyashita A; Heeringa M; Onkels H; Groenendaal D; Verheggen F; van Marle S; Usui T
    Xenobiotica; 2013 Jun; 43(6):534-47. PubMed ID: 23167531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
    Konishi N; Hiroe K; Kawamura M
    Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies.
    Herbert JM; Bernat A; Dol F; Hérault JP; Crépon B; Lormeau JC
    J Pharmacol Exp Ther; 1996 Mar; 276(3):1030-8. PubMed ID: 8786532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
    Parry TJ; Huang Z; Chen C; Connelly MA; Perzborn E; Andrade-Gordon P; Damiano BP
    Blood Coagul Fibrinolysis; 2011 Dec; 22(8):720-6. PubMed ID: 21986468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of food on the pharmacokinetics of darexaban, an oral direct factor Xa inhibitor, in healthy Japanese subjects.
    Kadokura T; Taniuchi Y; Inoue H; Saito M; Iwahana M; Yamada S; Urae A; Nakamura M
    Int J Clin Pharmacol Ther; 2013 Mar; 51(3):200-6. PubMed ID: 23211396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel oral anticoagulants: focus on the direct factor Xa inhibitor darexaban.
    Apostolakis S; Lip GY
    Expert Opin Investig Drugs; 2012 Jul; 21(7):1057-64. PubMed ID: 22616561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein.
    Groenendaal D; Strabach G; Garcia-Hernandez A; Kadokura T; Heeringa M; Mol R; Eltink C; Onkels H
    Clin Pharmacol Drug Dev; 2014 May; 3(3):194-201. PubMed ID: 27128609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model.
    Suleymanov OD; Szalony JA; Salyers AK; LaChance RM; Parlow JJ; South MS; Wood RS; Nicholson NS
    J Pharmacol Exp Ther; 2003 Sep; 306(3):1115-21. PubMed ID: 12829728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban: a new oral factor Xa inhibitor.
    Perzborn E; Roehrig S; Straub A; Kubitza D; Mueck W; Laux V
    Arterioscler Thromb Vasc Biol; 2010 Mar; 30(3):376-81. PubMed ID: 20139357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa.
    Taniuchi Y; Sakai Y; Hisamichi N; Kayama M; Mano Y; Sato K; Hirayama F; Koshio H; Matsumoto Y; Kawasaki T
    Thromb Haemost; 1998 Mar; 79(3):543-8. PubMed ID: 9531037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.